The Life Science Group Addlife today signed an agreement with Wellspect HealthCare to acquire their operations in the product areas surgery and respiration. The agreement means that Addlife acquires a number of market-leading niche products with associated rights and customer agreements in several geographic markets.
The business has a turnover of approximately EUR 17 million, of which eight markets in Europe and Australia account for more than 90 percent of sales. The acquisition is expected to be completed during the first quarter of 2019.
